While anti‐CD47 antibody (B6H12) can efficiently block the interaction of CD47 and SIRPα, the combination with osimertinib dramatically increased the phagocytosis in vitro and enhanced the antitumor effect in vivo.[248] Similarly, EGFR‐sensitizing mutation (Ex19Del or L858R) or EGFR‐TKI resistance promotes NSCLC tumors' escape from innate immune attack via upregulating CD47. This evidence concerns the gene EGFR and non-small cell lung carcinoma.